¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"familial screening"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • familial adenomatous polyposis
    °¡Á·¼º»ùÁ¾Æú¸³Áõ
  • familial aminoglycoside ototoxicity
    °¡Á·¼º¾Æ¹Ì³ë±Û¸®Äڽõå±Íµ¶¼º
  • familial amyloid neuropathy
    °¡Á·¼º¾Æ¹Ð·ÎÀ̵å½Å°æº´(Áõ)
  • familial annulare erythema
    °¡Á·¼ºÀ±»óÈ«¹Ý, °¡Á·¼º°í¸®È«¹Ý
  • familial cardiomyopathy
    °¡Á·¼º½ÉÀå±ÙÀ°º´(Áõ), °¡Á·¼º½É±Ùº´(Áõ)
  • familial dysautonomia
    °¡Á·¼ºÀÚÀ²½Å°æÀÌ»ó(Áõ)
  • familial goiter
    °¡Á·¼º°©»ó»ùÁ¾
  • familial hemophagocytic lymphohistiocytosis
    °¡Á·¼ºÀûÇ÷±¸Æ÷½Ä¼º¸²ÇÁÁ¶Á÷±¸Áõ½ÄÁõ
  • familial paroxysmal polyserositis
    °¡Á·¼º¹ßÀÛ´Ù¹ßÀ帷¿°
  • familial polyposis
    °¡Á·¼ºÆú¸³Áõ
  • familial progressive hearing loss
    °¡Á·¼ºÁøÇ೭û
  • familial tremor
    °¡Á·¼º¶³¸²
  • idiopathic familial fibromatosis
    Ư¹ß°¡Á·¼¶À¯Á¾Áõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • familial dysautonomia
    °¡Á·ÀÚÀ²½Å°æ±â´ÉÀÌ»ó
  • endogenous familial hypertriglyceridemia
    ³»Àΰ¡Á·°íÁß¼ºÁö¹æÇ÷Áõ
  • familial eosinophilia
    °¡Á·È£»ê±¸Áõ°¡Áõ
  • familial annulare erythema
    °¡Á·À±»óÈ«¹Ý, °¡Á·°í¸®È«¹Ý
  • familial pigmented purpuric eruption
    °¡Á·»ö¼ÒÀڹݹßÁø
  • familial
    °¡Á·-
  • familial hyperlipoproteinemia
    °¡Á·°íÁö¹æ´Ü¹éÇ÷Áõ
  • familial hyperuricemia
    °¡Á·°í´¢»êÇ÷Áõ
  • familial tremor
    (¢¡essential tremor) º»Å¶³¸², À¯Àü¶³¸², ¿øÀθ𸦶³¸²
  • familial adenomatous polyposis
    °¡Á·»ùÁ¾Æú¸³Áõ
  • familial paroxysmal polyserositis
    °¡Á·¹ßÀÛ´Ù¹ßÀ帷¿°
  • familial progressive hearing loss
    °¡Á·ÁøÇ೭û
  • idiopathic familial fibromatosis
    Ư¹ß°¡Á·¼¶À¯Á¾Áõ
  • transient familial neonatal hyperbilirubinemia
    Àϰú¼º°¡Á·½Å»ý¾Æ°íºô¸®·çºóÇ÷Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hypercholesterolemia,familial
    °¡Á·¼º(Ê«ðéàõ)
  • idiopathic familial fibromatosis
    Ư¹ß¼º °¡Á·¼º ¼¶À¯Á¾Áõ.
  • idiopathic familial fibromatosis
    Ư¹ß¼º °¡Á·¼º ¼¶À¯Á¾Áõ
  • infantile amaurotic familial idiocy
    ¿µ¾Æ¼º Èæ³»À强 °¡Á·¼º ¹éÄ¡.
  • infantile amaurotic familial idiocy
    ¿µ¾Æ¼º Èæ³»À强 °¡Á·¼º ¹éÄ¡.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • screening test
    ¼±º°°Ë»ç
  • sun screening agent
    ž籤(¼±)Â÷´Ü<ºÀ¼â>Á¦, Àϱ¤Â÷´Ü<ºÀ¼â>Á¦, Â÷±¤Á¦
  • test, screening hearing
    ¼±º°Ã»·Â°Ë»ç
  • urine screening
    ¿ä¼±º°
  • amaurotic familial idiocy =Tay-Sachs disease
    °¡Á·¼º Èæ³»Àå ¹éÄ¡(Ê«ðéàõýÙÒ®î¡ÛÜöÁ).
  • amaurotic familial idiocy =Tay-Sachs disease
    °¡Á·¼ºÈæ¾Ï½Ã¹éÄ¡(Ê«ðéàõýÙÒ®î¡ÛÜöÁ).
  • benign familial pemphigus
    ¾ç¼º °¡Á·¼º(åÐàõ Ê«ðéàõ) õÆ÷â(ô¸øÞóê)
  • breast/ovarian familial cancer syndrome
    À¯¹æ/³­¼Ò °¡Á·¼º ¾ÏÁõÈıº
  • chronic familial jaundice
    ¸¸¼º°¡Á·¼º Ȳ´Þ(¡­Ê«ðéàõüÜÓ¸).
  • diffuse familial comedo
    ±¤¹üÀ§ °¡Á·¼º ¸éÆ÷
  • dysbetalipoproteinemia.familial
    °¡Á·¼ºÀÌ»óº£Å¸¸®Æ÷ÇÁ·ÎÅ×ÀÎÇ÷Áõ
  • endogenous familial hypertriglyceridemia
    ³»Àμº °¡Á·¼º °íÆ®¸®±Û¸®¼¼¸®µå Ç÷Áõ
  • familial
    °¡Á·¼º(Ê«ðéàõ)ÀÇ
  • familial adenomatous polyposis
    °¡Á·¼º¼±Á¾¼º¿ëÁ¾Áõ.
  • familial adenomatous polyposis
    °¡Á·¼º ¼±Á¾¼º Æú¸³Áõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DDST Denver Developmental Screening Test; Denver ¹ß´Þ Æò°¡ °Ë»ç(¹ßÀ° ¼±º° °Ë»ç)
MAST Michigan Alcohol Screening test
ACCESS Ambulatory Care Clinic Effectiveness Systems Study; automated cervical cell screening system
AMS ablepharon-microstomia syndrome; acute mountain sickness; adenosylmethionine synthetase; aggravated ...
BCSI breast cancer screening indicator
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EPSDT Early and Periodic Screening Diagnosis and Treatment
HTS High Throughput Screening
MSS Maternal Serum Screening
MAST Michigan Alcohol Screening Test
MAST Michigan Alcoholism Screening Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • familial genuine malfomation of root
    °¡Á·¼º ¼±Ãµ¼º Ä¡±Ù ±âÇü
    µ¿ÀǾî=dentinal dys
  • familial hemolytic anemia
    °¡Á·¼º ¿ëÇ÷¼º ºóÇ÷
  • familial histocytic dermatoarthritis
    °¡Á·¼º Á¶Á÷±¸¼º ÇǺΠ°üÀý¿°
  • familial hyperlipoproteinemia
    °¡Á·¼º °úÁöÁú´Ü¹éÇ÷Áõ
  • familial hypophosphatemic rickets

    familial leiomyomatosis cutis et uteri (°¡Á·¼º ÇǺΠÀڱà ±ÙÁ¾Áõ

  • familial Mediterranean fever
    °¡Á·¼º ÁöÁßÇØ ¿­
  • familial neutropenia
    °¡Á·¼º È£Áß±¸ °¨¼ÒÁõ
  • familial polyposis
    °¡Á·¼º Æú¸³Áõ
  • familial progressive sensorineural hearing loss
    °¡Á·¼º ÁøÇ༺ °¨°¢ ½Å°æ¼º ³­Ã»
  • familial teleangiectasis
    °¡Á·¼º ¸»ÃÊÇ÷°ü È®Àå, °¡Á·¼º ¸»ÃÊÇ÷°ü È®ÀåÁõ
  • fatal familial insomnia
    Ä¡¸íÀû °¡Á·¼º ºÒ¸éÁõ
    ºÒ¸éÁõ°ú ÀÚÀ²½Å°æ Àå¾Ö°¡ ÁÖ Áõ»óÀÌ°í ¸ðµç ȯÀÚ¿¡¼­ PrP À¯ÀüÀÚÀÇ º¯À̸¦ È®ÀÎÇÒ ¼ö ÀÖ´Ù. ÇüÅÂÇÐÀû ¼Ò°ßÀº º¸Åë ½Ã»ó¿¡¼­¸¸ °üÂûµÇ´Âµ¥ ½Å°æ ¼¼Æ÷ÀÇ ¼Ò½Ç°ú ´õºÒ¾î ±³¼¼Æ÷°¡ Áõ½ÄÇϰí ÇØ¸é»ó º¯È­¸¦ º¸ÀδÙ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
drug screening Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
(12 Dec 1998)
drug screening assays, antitumour Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumour growth parameters in laboratory animals.
(12 Dec 1998)
benign familial chorea A rare, nonprogressive movement disorder characterised by chorea and athetosis appearing in early childhood, most commonly manifested as gait ataxia and upper limb coordination. Intellect is unaffected. Probably autosomal-dominance inheritance with incomplete penetrance.
(05 Mar 2000)
benign familial chronic pemphigus Recurrent eruption of vesicles and bullae that become scaling and crusted lesions with vesicular borders, predominantly of the neck, groin, and axillary regions; autosomal dominant inheritance, presenting in late adolescence or early adult life.
Synonym: Hailey-Hailey disease.
(05 Mar 2000)
benign familial icterus Mild jaundice due to increased amounts of unconjugated bilirubin in the plasma without evidence of liver damage, biliary obstruction, or haemolysis; thought to be due to an inborn error of metabolism in which the excretion of bilirubin by the liver is defective, ascribed to decreased conjugation of bilirubin as a glucuronide or impaired uptake of hepatic bilirubin.
Synonym: benign familial icterus, constitutional hepatic dysfunction, Gilbert's disease, Gilbert's syndrome, Hebra's disease.
(05 Mar 2000)
cancer, breast, familial A number of factors have been identified that increase the risk of breast cancer. One of the strongest of these risk factors is the history of breast cancer in a relative. About 15-20% of women with breast cancer have such a family history of the disease, clearly reflecting the participation of inherited (genetic) components in the development of some breast cancers. Dominant breast cancer suceptibility genes, including BRCA1 and BRCA2, appear responsible for about 5% of all breast cancer.
(12 Dec 1998)
paralysis, familial periodic An autosomal dominant trait marked by recurring attacks of rapidly progressive flaccid paralysis. There are three types: I, associated with a fall in serum potassium levels (hypokalaemic periodic paralysis); II, associated with a rise therein (hyperkalaemic periodic paralysis, called also adynamia episodica hereditaria); and III, with normal levels (normokalaemic periodic paralysis).
(12 Dec 1998)
pemphigus, benign familial Rare hereditary disease characterised by recurrent eruptions of vesicles and bullae mainly on the neck, axillae, and groin. It exhibits autosomal dominant inheritance and is unrelated to pemphigus vulgaris though it closely resembles that disease.
(12 Dec 1998)
chronic familial icterus <haematology> A hereditary disorder that leads to a chronic haemolytic anaemia due to an abnormality in the red blood cell membrane.
This disorder is caused by a defective gene. Red cells are resistant to stress and rupture easily. Infants may appear jaundiced and pale. Fatigue, weakness and shortness of breath are other symptoms that may be seen in older patients. The spleen may also be enlarged.
Treatment includes splenectomy (removal of the spleen). After this is accomplished the life-span of the red blood cells returns to normal.
(27 Sep 1997)
chronic familial jaundice <haematology> A hereditary disorder that leads to a chronic haemolytic anaemia due to an abnormality in the red blood cell membrane.
This disorder is caused by a defective gene. Red cells are resistant to stress and rupture easily. Infants may appear jaundiced and pale. Fatigue, weakness and shortness of breath are other symptoms that may be seen in older patients. The spleen may also be enlarged.
Treatment includes splenectomy (removal of the spleen). After this is accomplished the life-span of the red blood cells returns to normal.
(27 Sep 1997)
chronic familial polyneuritis Inflammation of nerves related to infiltration by amyloid.
(05 Mar 2000)
mixed hyperlipoproteinaemia familial Type 5 hyperlipidemia, elevations of VLDL and chylomicrons found in plasma.
Synonym: mixed hyperlipidemia.
(05 Mar 2000)
progressive familial scleroderma A syndrome characterised by calcinosis cutis, Raynaud's phenomenon, sclerodactyly, and telangiectasia; usually due to scleroderma; autosomal dominant form of progressive systemic sclerosis.
(05 Mar 2000)
hypercholesterolaemia, familial A familial disorder characterised by increased plasma concentration of cholesterol carried in low density lipoproteins (ldl) and by a deficiency in a cell surface receptor which regulates ldl degradation and cholesterol synthesis. It is frequently associated with arcus senilis and premature atherosclerosis.
(12 Dec 1998)
hyperlipidemia, familial combined A disorder genetically distinct from the other inherited hyperlipidemias characterised by the type II or type IV lipoprotein pattern (the pattern may change from time to time and the lipid level may be normal at one time and abnormal at another time).
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á